At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Apraglutidedrug
Likely dose
Apraglutide 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Renal Function.
In Brief
A Phase 1 clinical trial evaluating Apraglutide for Chronic Kidney Disease. Completed, enrolled 16 participants across 2 sites.
Detailed Summary
Study of pharmacokinetics and safety of apraglutide in participants with normal and impaired kidney function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedJan 2021
Primary CompletionJul 2021
TodayJul 2026
First PostedJan 7, 2021
Enrollment StartDec 8, 2020
Primary CompletionJul 5, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.5 years ago
Interventions
Apraglutidedrug
Single dose of apraglutide 5 mg.